Universita di Bologna Trials

Universita di Bologna	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Martinelli, Giovanni

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Not yet recruiting

339

Europe, RoW

High intensity therapies, Low intensity therapies

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX

Acute Myeloid Leukemia, Relapse/Recurrence

01/28

HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting

2/3

463

Europe, US, RoW

Elenestinib, BLU-263, Placebo

Blueprint Medicines Corporation

Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis

06/28

ALL2418, NCT03610438 / 2018-003006-32: Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Recruiting

Europe

Inotuzumab Ozogamicin (IO)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Lymphoid Leukemia

11/22

PROTECT, NCT04363827 / 2020-001501-24: Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Active, not recruiting

2300

Europe

Hydroxychloroquine

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, University of Bologna

COVID19, Hydroxychloroquine, Prophylaxis, Treatment, SARS-CoV-2

06/21

09/21

V-FIRST, NCT03455504 / 2018-000392-33: Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

Active, not recruiting

124

Europe

Venetoclax

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

01/25

NCT05319587 / 2020-005493-10: Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)

Active, not recruiting

1/2

Europe

Liposomal Annamycin, Cytarabine

Moleculin Biotech, Inc., Moleculin Biotech, Inc.

Leukemia, Myeloid, Acute

08/23

04/25

CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN

Active, not recruiting

1/2

179

Europe, US

IMGN632

AbbVie

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm

09/23

12/26

IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting

1/2

218

Europe, US

Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto

AbbVie, Jazz Pharmaceuticals

Acute Myeloid Leukemia

04/26

INO-CD22, NCT03898128: ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate

Recruiting

N/A

120

Europe

Anti-CD22 Immunotoxin

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Acute Lymphoblastic Leukemia

06/21

09/21

NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Active, not recruiting

N/A

Europe

Immunogenic profile

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Acute Myeloid Leukemia

12/24

12/25

AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting

N/A

100

Europe

Functional tests, Next Generation Sequencing analysis, Microvesicles analysis

Azienda Ospedaliero-Universitaria di Parma

Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

03/25

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting

N/A

4000

Europe

Registration into the STREAM platform

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

07/32

INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

Recruiting

N/A

2000

Europe

clinical data and sample collection

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna

Haematologic Disease, Haematological Malignancy

02/25

Curti, Antonio

AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting

172

Europe

Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD

Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Acute Myeloid Leukemia With FLT3/ITD Mutation

12/22

08/25

NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting

322

Europe, Canada, US

Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF

Arog Pharmaceuticals, Inc.

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

10/24

IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Not yet recruiting

339

Europe, RoW

High intensity therapies, Low intensity therapies

Acute Myeloid Leukemia, Relapse/Recurrence

01/28

DEC GITMO, NCT04476199 / 2020-002297-26: Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

Active, not recruiting

100

Europe

Venetoclax and Decitabine

Gruppo Italiano Trapianto di Midollo Osseo, Abbvie, Janssen

Acute Myeloid Leukemia

02/23

06/25

NCT04342962 / 2020-001543-94: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Terminated

Europe

tagraxofusp

Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus

Acute Myeloid Leukemia

01/24

AML2521, NCT04867928 / 2021-002361-17: Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia

Recruiting

Europe

Venetoclax+azacitidine

Gruppo Italiano Malattie EMatologiche dell'Adulto, ABBVIE S.r.l., Fondazione GIMEMA Franco Mandelli Onlus

Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation

01/25

CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN

Active, not recruiting

1/2

179

Europe, US

IMGN632

AbbVie

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm

09/23

12/26

IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting

1/2

218

Europe, US

Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto

AbbVie, Jazz Pharmaceuticals

Acute Myeloid Leukemia

04/26

NKAML, NCT03955848: INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS

Recruiting

N/A

Europe

Alloreactive NK cell infusion, Alloreactive NK cells

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Adult Acute Myeloid Leukemia in Remission

05/19

05/22

AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting

N/A

100

Europe

Functional tests, Next Generation Sequencing analysis, Microvesicles analysis

Azienda Ospedaliero-Universitaria di Parma

Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic

03/25

GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting

N/A

104

Europe

Venetoclax plus HMA

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

12/22

12/23

NCT06814444: Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia

Recruiting

N/A

170

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Acute Leukemia

12/29

12/30

NCT04460963: Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches

Recruiting

N/A

Europe

Adrenomedullin

Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia

06/24

NCT06764589: Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood

Active, not recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Acute Myelocytic Leukemia

03/25

12/27

NCT06090786: Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Not yet recruiting

N/A

225

MRD assessment

Gruppo Italiano Malattie EMatologiche dell'Adulto

AML, Adult, Minimal Residual Disease

07/27

Perrone, Myriam

TUBA-WISP II, NCT04294927: TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Recruiting

N/A

3000

Europe, US, RoW

Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy

University Medical Center Nijmegen

BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer

02/40



	Diseases Companies Products Productz Mechanisms of Action Sites